NCT00920205

Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments

Phase 1 Study of MCP-3100 in Patients With Refractory or Relapsed Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Myrexis Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see how safe the study drug is and to determine the best dose to use in cancer patients in the future. The study drug is designed to reduce the activity of a protein known as "heat shock protein 90", or "Hsp90". Hsp90 is found in every cell in the human body and normally helps those cells (and the body) cope with stressful situations. In certain cancers, however, Hsp90 helps the cancer cells survive and grow. By reducing the activity of Hsp90, the study drug may slow the growth, and reduce the survival, of those cancer cells.

Detailed description

This is a dose escalation study. As subjects participating in the study tolerate a specific dose level, the new subjects entering will be given a higher dose of the study drug.

Conditions

• Cancer

Interventions

Type	Name	Description
DRUG	MPC-3100 (an Hsp90 inhibitor)	oral daily dose for 21 days in a 28-day cycle

Timeline

• Start date: 2009-06-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2009-06-15
• Last updated: 2011-10-14

Locations

3 sites across 1 country: United States